Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.61 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4848887 | 0.92 | KDR (0.62) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4852414 | 0.90 | KDR (0.61) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4843595 | 0.90 | KDR (0.63) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL632357 | 0.90 | KDR (0.73) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4849175 | 0.90 | KDR (0.56) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4847554 | 0.90 | KDR (0.58) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4844255 | 0.89 | KDR (0.66) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4850281 | 0.88 | KDR (0.65) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4842024 | 0.88 | KDR (0.58) | KDRCYP3A4RAF1LCKRET | |
| SCHEMBL4850925 | 0.82 | KDR (0.61) | KDRCYP3A4RAF1LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | claimed |
| WO-2006034075-A1 | (HYDRAZIDO) (AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063773-A1 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | claimed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388012-B2 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2006034075-A1 | (HYDRAZIDO) (AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063773-A1 | (Hydrazido)(amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063773-A1 | (Hydrazido)(amino)thiophene compounds | KIT, BRDT, BRCA1 | KDR 1955/4885CYP3A4 2237/4885RAF1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.